Kestra Medical Technologies Inc（KMTS.OQ）公布了截至2025年4月30日的季度财务报告。公司每股调整后亏损达2.21美元，远逊于六位分析师平均预期的0.52美元亏损。华尔街此前预测亏损区间为-0.65美元至-0.46美元每股。这一表现突显了公司盈利挑战。
在营收方面，公司录得1723万美元，轻松超越分析师预期的1575万美元。尽管营收亮眼，公司整体净亏损高达5440万美元。本季度，Kestra Medical股价累计下挫6.9%，反映市场对业绩的担忧。
分析师预期在过去三个月保持稳定，过去30天无任何修订。当前平均评级为“买入”，具体包括5个“强力买入”或“买入”，仅1个“持有”，无“卖出”或“强力卖出”。这一评级与先进医疗设备及技术同业的平均“买入”一致。华尔街设定的12个月目标价中值为28美元，较其最新收盘价15.43美元高出44.9%，表明长期信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.